Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 21 chart positions in 21 markets.
By chart position
- 🇬🇧GB · Tech News#9830K to 100K
- 🇪🇸ES · Tech News#11100K to 300K
- 🇰🇷KR · Tech News#6210K to 30K
- 🇫🇷FR · Tech News#1051K to 10K
- 🇳🇱NL · Tech News#1101K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
58K to 195K🎙 Daily cadence·193 episodes·Last published 6d ago - Monthly Reach
Unique listeners across all episodes (30 days)
194K to 651K🇪🇸46%🇬🇧15%🇭🇺15%+18 more - Active Followers
Loyal subscribers who consistently listen
77K to 260K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 15 epsHost
Recent guests
Recent episodes
BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler
Jun 19, 2026
40m 49s
Advancing corticosteroids and hormonal therapies for supply and scale
Jun 12, 2026
27m 03s
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
Jun 5, 2026
43m 33s
World MS Day Special: Immunic reveals new hope for progressive MS
May 29, 2026
27m 30s
The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
May 22, 2026
38m 49s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/19/26 | BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler | This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and fund innovative therapies. My guest is Werner Lanthaler, Founder and CEO of WLAN Holding. Werner spent 15 years as CEO of Evotec SE, scaling the company from 200 employees and €40 million revenue to over 5,000 staff and €800 million. He previously served... | 40m 49s | ||||||
| 6/12/26 | Advancing corticosteroids and hormonal therapies for supply and scale✨ | corticosteroidshormonal therapies+3 | Olivier Roux | CuriaLabiotech | — | corticosteroidshormonal therapies+7 | — | 27m 03s | |
| 6/5/26 | Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media✨ | biotech mediaLabiotech story+4 | Joachim Eeckhout | LabiotechKnowbio+1 | BerlinFrance | biotechmedia+5 | — | 43m 33s | |
| 5/29/26 | World MS Day Special: Immunic reveals new hope for progressive MS✨ | multiple sclerosisbiotechnology+4 | Dr. Daniel Vitt | Immunic Therapeutics | multiple sclerosis | multiple sclerosisImmunic Therapeutics+5 | — | 27m 30s | |
| 5/22/26 | The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data✨ | drug discoveryAI in biotech+3 | Quin WillsStéphane Barges | Ochre BioLexogen | — | drug discoveryAI+3 | — | 38m 49s | |
| 5/15/26 | Freeze variability, not progress: strengthen your cell therapy supply chain from the start✨ | cell therapysupply chain+3 | Dominic Clarke | IntegriCellCryop | — | cell therapysupply chain+3 | — | 30m 25s | |
| 5/7/26 | Making labs smarter for scientific breakthroughs✨ | lab managementvirotherapy+3 | Ryan Cawood | Lab ThreadOXGENE+2 | — | lab managementvirotherapy+3 | — | 30m 48s | |
| 4/30/26 | How Epicrispr is leveraging CRISPR without cutting DNA✨ | CRISPRepigenetic editing+3 | Dr Stanley Qi | EpicrisprLabiotech | — | CRISPRepigenetic editing+3 | — | 33m 03s | |
| 4/24/26 | Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases✨ | vascular diseasesclustering antibodies+3 | Patrick Andre | Diagonal TherapeuticsPfizer+3 | — | Diagonal Therapeuticsvascular biology+3 | — | 31m 10s | |
| 4/17/26 | Argobio: the venture model building Europe’s next biotech champions✨ | biotechventure capital+3 | Thierry Laugel | KurmaArgobio+2 | — | biotech championsventure model+3 | — | 42m 00s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/10/26 | Multi-agent AI delivers reliable and scalable insights for single-cell omics✨ | AI in biopharmasingle-cell omics+3 | Parashar Dhapola | Nygen AnalyticsLund University | LundSweden | AIbiopharma+5 | — | 43m 42s | |
| 4/2/26 | Nionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight✨ | gene therapykidney disease+3 | Magdalena Tyrpien | Nionyx BioBIO-Europe Spring+1 | Lisbon | Nionyx Biokidney gene therapy+5 | — | 28m 35s | |
| 3/27/26 | HaemaLogiX - precision immunotherapy for multiple myeloma✨ | immunotherapymultiple myeloma+3 | Dr Rosanne Dunn | HaemaLogiXLabiotech | — | immunotherapymultiple myeloma+4 | — | 43m 13s | |
| 3/20/26 | How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray✨ | flu protectionintranasal antibody spray+3 | Koenraad WiedhaupClarissa Koch | Leyden LabsScience Translational Medicine | — | Leyden Labsintranasal spray+5 | — | 32m 30s | |
| 3/13/26 | How to optimize your biotech company for partnering, licensing, and business success✨ | biotechpartnerships+4 | Janita Good | FieldfisherPhynova+2 | — | biotechpartnerships+4 | — | 42m 23s | |
| 3/6/26 | Reversing tumor immunosuppression with next-gen GPCR modulation✨ | tumor immunosuppressionGPCR modulation+4 | Sean MacDonald | Kainova TherapeuticsDomain Therapeutics | — | tumor immunosuppressionGPCR+5 | — | 34m 14s | |
| 2/27/26 | Misinformation is a public health crisis - here's how to fix it | Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in i... | 50m 03s | ||||||
| 2/20/26 | Accelerating rare disease cures with ASOs, gene editing, and AI | Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK Oxford Neuromuscular Centre and the Oxford-Harrington Rare Disease Centre, a groundbreaking partnership between the University of Oxford and Harrington Discovery Institute dedicated to accelerating therapies for rare genetic diseases affecting millions... | 48m 53s | ||||||
| 2/13/26 | Using AI to crack undruggable drug targets | As we mark the International Day of Women and Girls in Science, we welcome Avital Sharir-Ivry, Co-Founder and Chief Scientific Officer of ProPhet, an innovative Israeli startup launched in late 2024 from the AION Labs venture studio. With a PhD in computational biology and drug research, Avital brings deep expertise in structural biology, enzyme design, and evolutionary bioinformatics to her role leading ProPhet's scientific efforts. ProPhet itself is changing small molecule drug discovery by... | 32m 58s | ||||||
| 2/6/26 | How Eli Lilly's biotech collaboration model is rewriting early-stage innovation | Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thomas has spent his career bridging bold discovery science with rigorous development, first in academia and clinical practice, then at Lilly since 2015. Lilly ExploR&D represents new thinking in the pharma-biotech collaboration model: a shared-risk, deep scientific partnership designed specifically for early-stage biotechs. It provides full-... | 35m 46s | ||||||
| 1/30/26 | Building a smart oncology pipeline with Cumulus Oncology | Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh. With over 25 years of expertise in oncology drug development, Clare has built a remarkable career translating scientific breakthroughs into life-changing therapies. Cumulus Oncology is curating a risk-adjusted portfolio of preclinical assets focused on high unmet needs in oncology. Their platform-agnostic, approach prioritizes patient subgroups and precision medicine to boost success ... | 34m 42s | ||||||
| 1/23/26 | Top 5 trends that will drive biopharma in the next decade with Tim Opler | Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel's Global Healthcare Group, he's advised on over 150 deals totaling more than $100 billion, shaping major M&A, licensing, and financings in life sciences. Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we'll dive into his December ... | 36m 25s | ||||||
| 1/16/26 | Labiotech's 15 biopharma companies to watch in 2026 | Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be the ones to watch in 2026. Now you can read that article at Labiotech-dot-EU, and we’ve linked it in the show notes here in your podcast player, too, but on today’s episode I’m joined by Jules, Roohi, and Willow who explain ... | 41m 28s | ||||||
| 1/9/26 | M Ventures: pharma CVC and biotech innovation in 2026 | Welcome to our first episode for 2026. Today, we're joined by Hakan Goker, Managing Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biotech investing, Hakan has driven transformative deals in oncology, autoimmune diseases, and beyond, including standout 2025 investments like FoRx Therapeutics and portfolio milestones such as Artios' FDA Fast Track designation. As we kick off 2026 at Beyond Biotech, Hakan shares insights on corp... | 35m 43s | ||||||
| 12/19/25 | Johnson & Johnson’s hematology portfolio: breakthroughs to watch | Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker. Today, though, I’m joined by Ester in t’Groen of Johnson & Johnson. Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&J presented over 60 abstracts, Ester shares insights into the company's portfolio and the advances that the compa... | 34m 25s | ||||||
Showing 25 of 202
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
21 placements across 21 markets.
Chart Positions
21 placements across 21 markets.